Arca
Skip to content

Fibrodysplasia ossificans progressiva (fop)

Drug research and approvals for fibrodysplasia ossificans progressiva (fop): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 4 studies of fibrodysplasia ossificans progressiva (fop) are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 3 approved and 2 open orphan designations naming it.

  • Recruiting worldwide: 4
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 3
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Dec 21, 2021Rollover study; multicentre, phase III, open-label study to further evaluate the safety and efficacy of palovarotene capsules in male and female participants…PALOVAROTENEIpsenClosed
Nov 25, 2021A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of incb000928 in participants with…ZILURGISERTIB (INCB000928)Incyte CorporationOngoing
Dec 30, 2020A phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy adn safety of 2 dosage regimens of oral ipn60130 for the…FIDRISERTIB (IPN60130)CLEMENTIA PHARMACEUTICALS INC.Closed
Aug 10, 2018A randomized, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and effects on heterotopic bone formation of regn2477 in patients…REGN2477RegeneronPending
Nov 8, 2017A phase 3, efficacy and safety study of oral palovarotene for the treatment of fibrodysplasia ossificans progressiva (fopPALOVAROTENECLEMENTIA PHARMACEUTICALS INC.Closed

FDA Orphan Designations

Approved first, then open designations, newest first
Sep 25, 2026Atebriozto reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with…Mirum Pharmaceuticals, Inc.Approved
Aug 19, 2026Pasatruto reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans…Regeneron Pharmaceuticals, Inc.Approved
Aug 16, 2023Sohonosfor the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10…Ipsen Biopharmaceuticals, Inc.Approved
Oct 22, 2026saracatinibtreatment of fibrodysplasia ossificans progressivaMass General BrighamDesignated
Mar 19, 2024AndecaliximabTreatment of fibrodysplasia ossificans progressivaashibio IncDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.